Who is sponsoring NCT06022198?

NCT06022198 is sponsored by Mohamed Abd Elmoniem Mohamed.

What drugs are being tested in NCT06022198?

Interventions in NCT06022198: Bronchoalveolar Lavage.

What condition does NCT06022198 study?

NCT06022198 studies Bronchoalveolar Lavage.

Is NCT06022198 still recruiting?

NCT06022198 is currently completed. Last updated 1 September 2023.

Last reviewed 2023-09-01 · How we verify

NCT06022198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchoalveolar Lavage in Recovered From COVID-19 Pneumonia

Completed NA Last updated 1 September 2023

What this trial tests

NA trial testing Bronchoalveolar Lavage in Bronchoalveolar Lavage in 50 participants. Completed in 1 January 2023.

Timeline

1 January 2021

Primary endpoint
1 January 2022

1 January 2023

Quick facts

Lead sponsor	Mohamed Abd Elmoniem Mohamed
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	1 January 2021
Primary completion	1 January 2022
Estimated completion	1 January 2023
Sites	1 location across Egypt

Drugs / interventions tested

Bronchoalveolar Lavage — full drug profile →

Conditions studied

Bronchoalveolar Lavage — all drugs for Bronchoalveolar Lavage →

Sponsor

Mohamed Abd Elmoniem Mohamed

Who can join

18 and older, any sex, with Bronchoalveolar Lavage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronaviruses such as SARS-CoV2, MERS-CoV, and SARS-CoV can cause significant morbidity and mortality in infected persons. Lung is the most common site of infection for these viruses, which may manifest as acute respiratory distress syndrome and mortality. Pulmonary involvement is also responsible for the high viral transmission The aim of this study is to evaluate BAL in post-acute COVID-19 patients for:Cytological and cellular patterns. Microbial analysis for possibility of presence of bacterial, mycobacerial or fungal co-infection.PCR for corona virus

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Bronchoalveolar Lavage

Trials testing the same drug.

NCT06726356 — Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis. · NA · recruiting
NCT07130110 — BAL Contribution to Lung Cryo-TBB in ILD · NA · completed
NCT02818049 — Cardiopulmonary Effects of Bronchoalveolar Wash on Patients With Acute Respiratory Distress Syndrome · NA · terminated

Other recruiting trials for Bronchoalveolar Lavage

Currently open trials in the same condition.

NCT06506617 — HCAPPED I: HCAP-Pcr in Emergency Department · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06022198 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mohamed Abd Elmoniem Mohamed
Last refreshed: 1 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06022198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing